GGLP1 Base

Saxenda

liraglutide · Novo Nordisk
FDA approved 2014Once dailyChronic weight management

Saxenda is one of the earlier GLP-1 medications, approved in 2014 for chronic weight management. Unlike the once-weekly semaglutide and tirzepatide drugs, Saxenda is injected once daily because liraglutide has a much shorter half-life — around 13 hours. Average weight loss in trials was around 5-8% at one year, less than newer weekly drugs but still meaningful for many patients.

Reference dose ladder · Once daily
Week 1
0.6 mg
1 weeks
Week 2
1.2 mg
1 weeks
Week 3
1.8 mg
1 weeks
Week 4
2.4 mg
1 weeks
Maintenance
3 mg
hold

Educational reference only — your prescriber sets your actual schedule.

How Saxenda works

Liraglutide is a GLP-1 receptor agonist. It enhances meal-time insulin release, suppresses glucagon, slows gastric emptying, and reduces appetite. Daily injections mean steadier-but-smaller peaks compared to weekly drugs, which some patients prefer for tolerability.

Dose schedule

Saxenda starts at 0.6 mg daily for the first week, then increases by 0.6 mg each week, reaching the maintenance dose of 3.0 mg by week 5. Reference ladder only — your prescriber sets your actual schedule.

Common side effects

Nausea is the most common; diarrhea, constipation, vomiting, headache, fatigue, dizziness, and injection-site reactions are also reported. Daily titration steps mean side effects come in a slower stair-step rather than the weekly jumps of semaglutide-based drugs.

Storage and handling

Refrigerated until first use. Once in use, store at room temperature (up to 86°F / 30°C) or refrigerated, and discard 30 days after first use.

Sources

Last reviewed: 2026-05-24

Tracking on the side

Pair this guide with the iOS app.

Log your shot day, track side effects against the day-of-cycle curve, and chart your weight — all on your iPhone, never in the cloud. One-time $14.99.

Coming soon to the App Store